

Index

Note: page numbers in **Boldface** type indicate images; those followed by *t* indicate tables

A

- Accurette endometrial sampler, **110**
- Actinomycetes and *Actinomyces*, 33, **35**
- Actinomycetes in patients with IUDs, 54
- Adenoacanthoma, 100, **107**
- Adenocarcinoma, **100-103**
endometrial, **107, 289**
histology and cytology, comparison in 1,825 women, 113*t*
in situ (AIS) of the cervix, **98-100, 98t**
malignant mesodermal mixed tumor (MMMT), 128-**129**
ovarian, **289**
subtypes, 100-101
- Adenoid cystic carcinoma, 101
- Adenoma malignum, 100, **101**
- Adenosquamous carcinoma, 100
- AGC *See* Glandular cells
- Allende, I.A.C. and Orías, O., 4
- ALTS triage study, 13-14
- Amplicor HPV assay, 322-323, 324*t*
- Amsel's criteria, 32
- Anatomic tropism, specific, of HPV, 180
- Aneuploidy, **232**
- Animal models and papillomaviruses, 248-250
- Anisokaryosis, **27, 69, 74, 75, 81, 89, 102**
- Anisokaryosis, marked, 76-77
- Anovulatory women, 142-143
- Antigen, **307**
- Anucleated squames, 45, **46**
- Apoptosis (cell death), 204
- Arias-Stella reaction, endocervical glands, 125, **126, 127**
- ASC-US and ASC-H (atypical squamous cells of undetermined significance), 63-**68, 67**
clinical trial, 13-14
diagnosis and differential criteria, 63-**68, 65t**
differential criteria between SIL and ASC-US, ASC-H, 65*t*
National Cancer Institute guideline regarding ASC, 63
- Aschheim and Zondek, 4
- Atrophy, **55, 56, 121**
- Atypical glandular cells (AGC) *See* Glandular cells
- Automated screening of Pap smears, 14-15, 146, 293-303
a brief history of cytology automation, 293-303, 293*t*
financial justification, 301-302
robotic risk management and automated systems, 302
screening systems overview, 297*t*
ThinPrep and SurePath methods, 277-278
- Automatic staining and coverslipping, **270-271**
- Ayre spatula, 12, **268**
- Ayre, J. Ernest (1910-1974), **8-10**

B

- Babeş, Aurel A. (1886-1961), **5**
- Babeş, Aurel A. and C. Daniel, abstract, 1928, **6**
- Bacterial vaginosis (BV), 31, 32-35
 Lactobacillus of Döderlein, **33**
 methods of detecting, 32*t*
- Balloon cells (Ayre, 1949), 69
- Benign changes, 44-56
- Bethesda System, The (TBS), 13-14
- Bethesda System, The, of 2001 (TBS 2001), 63,
 64*t*, 65*t*, 149*t*, 302
- Binucleated cells, 66, **67, 80, 81**
- Biohazardous human tissues, 346
- Biomarkers, 233-237
 deregulated viral oncogene expression in
 cervical epithelium, 233-237
 detection by immunocytochemistry, 342-**346**
 in screening of cervical cancer, 227-242, **241**
- Biopap QTS test, 330, **331, 332**
- Biopsy, colposcopy-directed, 142
- Bleeding, abnormal, 142
- Blue blobs, or degenerated parabasal cells, 55, **56**

C

- Cancer *See also* Carcinoma; Cervical cancer;
 Endometrial carcinoma; Squamous carcinoma;
 Uterine cancer
 diagnostic tests, 141, 142
 of the uterine corpus, 162-165
 worldwide frequency of new cases among
 women, 155*t*
- Candida (Torulopsis) glabrata*, (*C glabrata*), **40,**
 41, **48**
- Candida albicans* (*C albicans*), 39-41, **40, 48**
- Carcinoma
 adenocarcinoma, **100-103**
 adenocarcinoma in situ (AIS) of the cervix,
 98-100, 98*t*
 cervical carcinogenesis, 32, 35, 37, 69
 cervical carcinoma, unstained imprint, **2**
 choriocarcinoma, 54
 cytology of invasive squamous carcinoma, **88-90**
 endometrial carcinoma, 103-113, **106-108, 111**
 endometrial hyperplasia, 111-112
 invasive squamous carcinoma, 84-90, **85-89**
 keratinizing carcinoma, invasive, 84, **85, 88**
 large-cell invasive carcinoma and repair:
 differential diagnosis, 97*t*
 large-cell invasive squamous carcinoma, 84,
 85, 88-89, 97*t*
 microinvasive carcinoma, **86**
 neuroendocrine carcinoma, **132-133**
 sexual activity and related risk of SILs, 79-80
 small-cell invasive squamous carcinoma, 84,
 85, 89-90
- Cell cycle, 202-**204, 203**
 aberrant S-phase induction, **344**
 proteins and cervical neoplasia, 206-207, **209**
 tumor suppressor genes, 211
- Cell Theory, 1
- Cellular
 changes caused by chemotherapy, 51
 surveillance mechanisms, 203-205
- Centromeres, **205**
- Cervical cancer
 adenocarcinoma in situ (AIS) of the cervix,
 98-100, 98*t*
 age-specific incidence rates, US women, 163*t*
 biomarkers in screening of cervical cancer,
 227-242
 C trachomatis and malignant changes in
 cervical epithelium, 35
 cervical intraepithelial neoplasia (CIN), **228**
 cyclins in cervical neoplasia, 207*t*
 descriptive epidemiology, **155-162**
 detection by direct visual inspection, 146-147,
 150
 distribution of high-risk HPV types in cervical
 cancer, **230**
 genes involved in cervical carcinogenesis,
 207-122
 heterozygosity, loss of, 214

- history of high-risk patients and automated screeners, 298, 298t
- HPV as primary screening tool, 147-148
- HPV, human papilloma virus vaccines, 143-145, 247-257
- identification of differentially expressed genes, 234-237, **235**
- imprinting, loss of, 214
- incidence rates, US women with cervical and endometrial cancer, 157t, 163t, 164t
- mortality rates in developing countries, 201
- multistep process of cervical carcinogenesis, **201**
- natural history of squamous cervical cancer, 140-141
- novel cervical cancer screening technologies, 227-229
- oral contraceptives as risk factor, 159-160
- prevention options for, 143-150
- proteins and cervical neoplasia, 206-207
- risk factors for, 158-162
- strategies for countries with low resources, 148-150
- tobacco smoking as risk factor, 159
- triage screening, for borderline smears and HPV, 148, 149t
- unstained imprint, **2**
- Cervical epithelium
- cellular changes, 35
 - cervicitis, follicular or lymphocytic, 47, **48**
 - koilocytosis, koilocytes, 69-71
- Cervical intraepithelial neoplasia (CIN), 32, 35, 42
- Cervicography, 147
- Cervix, **22-29**
- C trachomatis* (CT) and changes in cervical epithelium, 35
 - cervical amebiasis and *Entamoeba histolytica*, **44**
 - cervicitis, 47, **48**
 - cytology, **25-29**
 - cytology on routine VCE smear, 104-107, 269
 - decidualization of the cervical stroma, 52, **53**
 - electrocoagulation, cryosurgery, and laser vaporization, 52
 - fornix, fornices, **19, 22**
 - histology, **23-25**
 - histopathogenesis of HPV infections, 182-184
 - pseudodecidualization of the cervix, 53
 - SIL and ASC-US, ASC-H, differential criteria between, 65t
 - SILs, squamous intraepithelial lesions of the cervix, 63-90
 - transformation zone, **22**, 182-184, 230, **231**
- Checkpoints of cellular surveillance, 203, **204**
- Chemotherapy, 51
- Chemotherapy and cellular changes, 51, **52**
- Chlamydia trachomatis* (CT), 35-36, **37**
- C trachomatis* in Pap smear, **36**
 - comparison of viruses, chlamydiae, and bacteria, 36t
 - methods of detecting, 36
- Chloroma, vaginal, **131**
- Choriocarcinoma, 54, **125, 126**
- Chromatin structure, disruption caused by chemotherapy, 51
- Chromosomal aberrations, structural, 233-234
- Chromosomes, **205**
- Clear-cell (mesonephric) adenocarcinoma, 101, 103
- CLIA; Clinical Laboratory Improvement Act (1967) and Amendments (1988), 294-295, 294t
- Cloning, molecular, 169
- Clue cells (*Gardnerella vaginalis*), 33, **34**
- Colposcopy-directed biopsy, 142
- Columnar epithelium, **25, 26, 27**
- Comparison of viruses, chlamydiae, and bacteria, 36t
- Computer devices: imagers and screeners, 289-291
- Computer-assisted rescreening with PapNet and AutoPap, 283
- Cryosurgery, 52
- Cryotherapy, 142
- Cycles, endocrine and menstrual, **21**
- Cyclins in cervical neoplasia, 207t, **209**
- Cytoanalyzer, 293

- Cytologic specimens
 for HPV PCR testing, 333-334
 liquid-based preparations, **14**
 procurement of, 11-12, **268-269**, 284-289
 quality assurance (QA) in cervical cytology, 265-280
- Cytology *See also* Hormonal cytology
 assessment of hormonal activity
 after menopause, **122**
 at birth, **117**
 at puberty, **118**
 during pregnancy, **120-122**
 during the reproductive years, **118-120**
 in childhood, **117-118**
 automated screening systems, 293-303, 293*t*
 automation, 14, 15, 146, 295*t*, **296**
 benign changes, 44-56
 choriocarcinoma seen on smears, **125**, **126**
 comparison of histology and cytology in 1,825 women, 113*t*
 effects of estrogen, **52**, **56**, **119**
 effects of progesterone, **119**
 endometrial cytology on routine VCE smear, 104-107
 endometrial sampling over a 15-year period, 112*t*
 Federal laws governing, 294, 294*t*, 295*t*
 gynecologic liquid-based preparations, **14**
 HPV-induced changes, 69-79
 immunocytochemical detection of biomarkers, 342-346
 immunocytochemistry as screening tool, **237-242**
 inflammation, 46-48, **47**
 interpretation of hormonal patterns, **122-123**
 non-gynecological, 51
 of invasive squamous carcinoma, **88-90**
 reporting endometrial cell changes, 55
 reporting terminologies for cervical cytology and pathology, 149*t*
 reports and record keeping, 13-14, 266, **272**
 screening for malignant melanoma, 130-131
 the beginning of the current era of cytopathology, 293*t*
 to confirm fetal death in utero, **121**, **122**, 124
- Cytolysis, **33**
- Cytomegalovirus, 42
- Cytopipette, 12
- Cytoplasmic vacuolization, 51, **52**
- Cytotoxic T lymphocytes (CTL), 247
- Cytotrophoblasts, 53-**54**, 124
- ## D
- Decidualization of the cervix, 52, **53**
- Degenerative vacuoles, **36**
- Dendritic cell (DC), 25
- Deregulated HPV infection, **229**, 232
- Developing countries
 cervical cancer mortality rates, 201
 detection of cervical cancer by direct visual inspection, 146-147, 150
 strategies for countries with low resources, 148-150
- Diabetes, uncontrolled, and yeast infections, 40
- Diagnostic Cytology and its Histopathologic Bases*, 1961, Leopold G. Koss, 9
- Dickinson, L.E., 2
- Digene Hybrid Capture II (HC II), 315-319
- Direct visual inspection (DVI) to detect cervical cancer, 146-147, 150
- DNA
 and RNA testing, 160-161, 310-**312**, **311**, 316*t*, 317
 HPV multiplexed assays, diagnostic tests, 342
 integration of HPV DNA, 179
 methylation, 234
 microarrays, genotyping, 337-341, **340**
 molecular cloning, recombinant papillomavirus, 169
 of high-risk HPV types, 161
 replication, 205-206
 restriction endonuclease analysis, 169
- Donné, Alfred François, 37
- Dot blot hybridization, 307, **308**, 309
- Dust ball (actinomycetes), **35**
- Dyskeratosis, 71-**79**, **72**, **73**, **306**
- Dysplasia, postradiation, 50, **51**

E

- Electrocoagulation, cryosurgery, and laser vaporization, 52
- Electron microscopy, 169, **306**
- Embryonal rhabdomyosarcoma: sarcoma botryoides, 126
- Endo-pap endometrial sampler, **110**
- Endobrush endometrial sampler, **110**
- Endocervical cells, normal, **95, 96**
- Endocervical lesions, **96-103, 288**
atypical glandular cells, 96, **97-103, 97t**
- Endocrine and menstrual cycles, **21**
- Endocyte endometrial sampler, **110**
- Endometrial aspiration techniques, 141
- Endometrial carcinoma, 103-113, **106-108, 111, 288**
adenoacanthoma, 100, **107**
adenocarcinoma, **107, 289**
endometrial lesions, classification of, 104t
endometrial stromal tumor, 128
estrogen, unopposed, as a risk factor for endometrial cancer, 164, 165
frequency of diagnosis in US, 140
incidence rates, US women with cervical and endometrial cancer, 162, 163t, 164t
indirect signs, 108-109
natural history of endometrial carcinoma, 141
prevention options for, 142-143
progestin for endometrial protection, 143
risk factors for, 104, 142, 162-165
screening, 11, **108-109, 112-113**
trends in relative 5-year survival rates, US women, 1960-2000, 163t
- Endometrial cells, atypical, **105-109**
- Endometrial cells, normal, **105, 110-111**
- Endometrial hyperplasia, 111-112, 141
- Endometrial sampling, 12, 109-113, **110-112**
cytology over a 15-year period, 112t
instruments, 12, **110, 113**
- Endometrial stromal cells, 108, 109, 110
- Endometrial stromal tumor, 128
- Endometritis, **111**
- Endometrium, **20-21, 103-113**
endometrial cytology on routine VCE smear, 104-107
endometrial glandular cells, 27, **28, 110**
- Entamoeba histolytica*, **44**
- Enterobius vermicularis*, **44**
- Epidemiology
age-specific incidence rates, US women with cervical cancer, 163t
and cancer prevention, 136
descriptive epidemiology of cervical cancer, **155-162**
epidemiologic classification of HPV genotypes, 175, 175t, 176t, 177, 177t
epidemiology of uterine cancers, **155-165**
evaluating strategies for prevention of uterine cancers, 136-137
- HPV and cervical cancer prevalence, **315**
- incidence of HPV in humans, 74
- incidence rates, US women with cervical and endometrial cancer, 157t, 163t, 164t
- of uterine cancers, 155-165
- Pap smear, efficacy of, 141
- prevalance of HPV infection, 186-190, 187t
- prevalence of herpes simplex virus (HSV) infections, 42
- risk factors for cervical cancer, 158-162
- trends in relative 5-year survival rates, US women with endometrial cancer, 1960-2000, 163t
- Epidermization and keratinization, 45
- Epigenetics, 212-214, **213, 234**
- Epithelia of Woman's Reproductive Organs: A Correlative Study of Cyclic Changes, The*
Papanicolaou, Traut and Marchetti, 1948, **4-6**

Epithelium

- columnar, **22, 23**
- female genital, 21, **22, 23**, 35
- SILs, squamous intraepithelial low- and high-grade lesions, **75-85**
- squamous, **22-25**

Estrogen

- effects of, **52, 56, 122-123**, 164, 165
- estrogen-containing oral contraceptive pills, 40
- estrogenic effect, **108-109**
- unopposed estrogen as a risk factor for endometrial cancer, 164, 165

Exfoliative cytology, first diagnosis, 1843, 1

Exodus, endometrial glandular cells, 28, **105**, 110

F

False-negative reports, litigation regarding, 13

Fetal death in utero, **121, 122**, 124

Filter in situ hybridization, 307, **308**

Fluorescence

- chain reaction (FCR), 341
- curve, **331**
- immunoassay, **343**

FocalPoint slide profiler, 289-290, 291, **296, 299, 300**

Fornix, fornices, **19, 22**

Friedlaender, C., 2

Fungi, 39-41

- Candida (Torulopsis) glabrata*, (*C glabrata*), **40, 41, 48**
- Candida albicans (C albicans)*, 39-41, **40, 48**
- Geotrichum, **40, 41**
- methods of detecting, 40
- risk factors of *Candida* infection, 39-40
- uncontrolled diabetes and yeast infections, 40

G

Gardnerella vaginalis (clue cells), 33, **34**

GeneTrack HPV DNA microarray, 339-**340**, 339t

Genome and genetics

- anogenital genotypes of HPV, human papilloma virus, **229-230**
- Candida albicans (C albicans)*, 39
- Candida albicans (C albicans)* genome, 39
- changes of the gene expression profile, 234
- Chlamydia trachomatis (C trachomatis)*, 36
- comparisons of viruses, chlamydiae, and bacteria, 36t
- deregulated viral gene expression, **232**
- deregulated viral oncogene expression, 233-234
- epidemiologic classification of HPV genotypes, 175, 175t, 176t, 177, 177t
- epigenetics, 212-214, **213**
- genes involved in cervical carcinogenesis, 207-122
- genetic and epigenetic changes, 212-214
- genome of *Candida albicans (C albicans)*, 39
- genomic organization of HPV, human papilloma virus, **173-147**
- herpes simplex virus (HSV), 41
- human papilloma virus (HPV), genital types of, 160-161
- identification of differentially expressed genes, 234-237, **235**
- imprinting, loss of, 214
- integration of HPV DNA, 179
- Linear Array HPV Genotyping Test, 323-326, **324, 325**, 326t
- MHC, major histocompatibility complex, 215-216
- mucosal genotypes of HPV, human papilloma virus, 230t
- Trichomonas vaginalis (T vaginalis)*, 37
- tumor suppressor genes, 211-212

Geotrichum, 40, **41**

Glandular cells

- adenocarcinoma, 100-103
- AGC (atypical glandular cells)-favor neoplastic, **97-98**, 97t, 100, 111, **112**
- AGC-favor neoplastic, **97-98**, 97t, 100, 111, **112**
- atypical-NOS (not otherwise specified), 96-**97**
- distinguishing endocervical from endometrial glandular cells, 95

- Glandular lesions of the uterus, 95-123
- Glassy cell carcinoma, 100
- Gluge, G., 2
- Glypicans, 177
- Gonadal hormones, maternal, effect on newborn girls, 117
- Gonococcus (*N gonorrhoeae*), 33
- Graham, Ruth M. (1917-1978), 7-8
- Granulocytes, 28, **29**
- Gravlee Jet Washer endometrial sampler, **12**
- Ground-glass cytoplasm, 100
- Ground-glass type nuclei, **44**
- ## H
- HC assay, 161
- Heparan sulfate proteoglycans, 177
- Herpes simplex virus (HSV), 9-10, 41-**43**
and cancer, 42
herpetic lesion of the cervix, **43, 44**
prevalence of HSV infections, 42
- Heterozygosity, loss of, 214
- Histiocytes, **28, 29**, 108, 109
- Histology
and cytology, comparison in 1,825 women, 113*t*
histologic aspects of HSIL (high-grade squamous intraepithelial lesion), **83-85**
laboratory safety, 346
routine, 279-280
- HIV, human immunodeficiency virus and *T vaginalis*, 37
- Hormonal activity, assessment of
after menopause, **122**
at birth, **117**
at puberty, **118**
during pregnancy, 120-122, **121**
during the reproductive years, **118-120**
in childhood, 117-118
- Hormonal cytology, 4-5, 4-6, 117-123
appearance of cervical smears after menopause, 120-**122, 121**
appearance of cervical smears during pregnancy, 120-**122, 121**
assessment of hormonal activity, 117-122
beginnings of, 2-4
cervical smear patterns by Papanicolaou, **4**
estrogenic effect, 108-**109, 119**
interpretation of the hormonal patterns, **122-123**
specimen collection, 117
witch's milk, 117
- Hormonal indexes, 4
- Hormone therapy, 52, **53, 54**
- Hormones
estrogen and endometrial cancer, 164
estrogen-containing oral contraceptive pills, 40
progesterone deficiency and endometrial cancer, 165
progesterin, for postmenopausal patients, 142
- HPV and cervical cancer prevalence, **315**
- HPV ISH assays, 312-314
- HPV PCR assays, 319-334
- HPV RNA assay, **334-337**
- HPV, human papilloma virus, 37, 41, 63
Amplicor HPV DNA test, 322-323, 324*t*
and intraepithelial lesions, 63, 80
and *T vaginalis*, 37
anogenital genotypes, 229-**230**
antigen, **307**
as risk factor for cervical cancer, 160-162
balloon cells (Ayre, 1949), 69
clearance, persistence, and progression of infection, 184-186
deregulated viral expression, **232**
detection approaches, 307-310
distribution of high-risk HPV types in cervical cancer, **230**
diversity of HPV and associated lesions, 180-184, **181, 183**
DNA of high-risk HPV types, 161
epidemiologic classification, 175, 175*t*, 176*t*, 177

- episomal form of HPV, 179
- genetic types, 160-161, 169, **170**
- genomic organization, **173-147**
- HPV as primary screening tool for cervical cancer, 147-148
- HPV immunoassay, **343**
- HPV multiplexed assays, 342
- HPV-induced cervical cancer, 9-10, 13-14, 69, **228**
- HPV-induced changes, 69-79
- immune biology of infections, 247-248
- immune responses and cancer, 216-218
- immunoassay and microspheres, **343**
- incidence of HPV in humans, 74
- integration of HPV DNA, 179
- koilocytotic atypia (Koss and Durfee, 1956), 69
- life cycle of HPV, 178-179
- mass screening, 147
- misdiagnosis of infection, 71
- molecular and serologic diagnosis of HPV infections, 305-347
- morphologic, physical, and chemical properties of, **171-177, 172**
- mucosal genotypes, 230*t*, **231**
- mucosal infection, phases of, 230, **231**
- nearcarcinoma (Ayre), 69
- need for routine screening, to diagnose SILs, 80
- ORFs, open reading frames, of HPV, 174*t*
- prevalance of HPV infection, 186-190, 187*t*, **230**
- propagation in tissue culture, 180
- sample collection for HPV detection, 309-310
- specific anatomic tropism, 180
- testing in clinical practice, 305-307
- testing in routine clinical laboratories, 309-310, 309*t*
- three phases of viral life cycle, **228, 230-231**
- triage, 148, 149*t*
- types, high- and low-risk, and progress of infection, 160, 175, 177, **228-233, 231**
- usefulness of HPV testing, 306-307
- vaccines, 143-145, 218, 247-257, 346
- virus-like particles (VLPs), 341-342
- HSIL, (high-grade squamous intraepithelial lesion, atypical dyskeratosis), 74, **75-79, 81-85**
- HSV, herpes simplex virus, 9-10
- Hybrid Capture II (HC II) test for HPV mass screening, 147, 315-319, **317, 318*t*, 319*t***
- Hybridization, 307-310, **311, 312**
- assay, HPV solution, 315-319
- Digene Hybrid Capture II (HC II), 315-319
- Hydatidiform mole, 54
- Hyperchromatism, 66, 68, **69, 81, 83**
- Hyperplasia, endometrial, 111-112, 113*t*
- I**
- IARC, of the World Health Organization, 161
- IFN pathway, 217
- Immune evasion, HPV, and cancer, 216-218
- Immune responses, 25, 247-250
- Immune system, 215-218
- immune biology of HPV infections, 247-248
- MHC, major histocompatibility complex, 215-216
- Immunocytochemical detection of biomarkers, 342-346
- Immunocytochemistry as screening tool, **237-242**
- Immunocytochemistry, immunohistochemistry, 343-346
- Imprinting, loss of, 214
- In situ hybridization (ISH), 233-234, 307, **308**
- commercial ISH assays, 314-316
- HPV ISH assays, 312-314
- principle of ISH, 313-314
- Ventana Inform HPV Assay, 314
- Infections, 31-44
- actinomycetes, 33, **35**
- Amsel's criteria, 32
- bacterial vaginosis (BV), 31, 32-35
- chlamydia trachomatis* (CT), 35-36
- clearance, persistence, and progression of HPV infection, 184-186
- comparison of viruses, chlamydiae, and bacteria, 36*t*
- deregulated HPV infection, **229, 232**

- differential diagnostic criteria of vaginal infections, 32*t*
- fungal infections, 39-41
- genital, 35
- high- and low-risk types, and progress of infection, **228-231**, 229-233
- HPV, human papilloma virus and intraepithelial lesions, 63, 69-70
- HPV, sexually transmitted infection (STI), 143-144
- in pregnant women, 40
- latent infection phase, HPV, **228**, 230, **231**
- misdiagnosis of infection with HPV, human papilloma virus, 71
- mixed or coccoid bacteria, 33, **34**
- molecular and serologic diagnosis of HPV infections, 305-347
- pathogenesis of HPV infections, 182-184, **183**
- prevalance of HPV infection, 186-190, 187*t*
- prevalence of herpes simplex virus (HSV) infections, 42
- productive infection phase, HPV, **228**, 230, **231**
- replicative infection phase, HPV, **228**, **231**, 233
- risk factors of *Candida* infection, 39-40
- Infections and other benign changes, 31-56
- Inflammation, 46-48, **47**, **66**
- Inocurette endometrial sampler, **110**
- Instruments
- for endometrial sampling, **12**, **110**
 - for Pap smear sampling, **268**
- Interleukin 18, IL-18, 217
- Intermediate squamous cells, **26**
- Invasive mole, 54, 125
- Invasive squamous carcinoma, 84-90, **85-89**
- clinical stages of, **85**
 - histologic classification, 84, **85**
- Ionizing radiation, 49-51, **50**, **51**
- acute stage, 49
 - chronic stage, 49-50
 - malignant mesodermal mixed tumor (MMMT), 128-129
 - postradiation dysplasia, 50-51
- Isaacs endometrial sampler, **110**
- IUDs (intrauterine contraceptive devices)
- and actinomycetes, 33, **35**
 - effects of, **54-55**
 - patient history, necessity for, 33, **35**
 - reporting endometrial cell changes caused by IUDs, 55
- ## K
- Karyorrhexis caused by chemotherapy, 51, **52**
- Keratinization and epidermization, 45, **46**
- anucleated squames, 45, **46**
 - keratinizing carcinoma, invasive, **88**
 - pearl formations, **73**
- Keratinocytes, 25
- Kinetochores, 205
- Koilocytosis, koilocytes, 69-71, **170**, 231
- "The Story of a Cell," Meisels, 1983, 69
 - koilocytotic atypia, 9-10, 69
 - misdiagnosis of infection with HPV, human papilloma virus, **71**
- Koss, Leopold G., *Diagnostic Cytology and its Histopathologic Bases*, 1961, 9
- ## L
- Laboratory safety, 346
- Lactobacillus acidophilus*, 33
- Lactobacillus* of Döderlein, **33**
- Langerhans cell (LC), 25, 217, 248
- Large-cell invasive squamous carcinoma, **88-89**, 97*t*
- Laser fulguration or ablation, 142
- Laser vaporization, 52
- Latent infection phase, HPV, **228**, 230, **231**
- Lebert, H. (1813-1878), 2
- Leiomyosarcoma, 126-128, **127**
- Lesions

- endocervical lesions, **96-103, 288**
- endometrial lesions, classification of, 104*t*
- glandular lesions of the uterus, 95-123
- herpetic lesion of the cervix, **43, 44**
- pregnancy-associated lesions, 124-126, **125-127**
- rare lesions of the uterus, 124-133
- SILs, (squamous intraepithelial lesions) low- and high-grade, **70, 71, 79-84, 286, 287**
- SILs, (squamous intraepithelial lesions) of the cervix, 63-90
- Linear Array HPV Genotyping Test, 323-326, **324, 325, 326*t***
- Liquid-based cytology, **14**, 145-146, 277-279, 283-291
- PapNet and AutoPap, 283
- ThinPrep and SurePath methods, 277-278, 284-**289**
- Litigation regarding false-negative reports, 13
- Loop electrosurgical excision procedure (LEEP), 142, 228
- LSIL (low-grade squamous intraepithelial lesion) triage study (ALTS), 13-14
- Lymphocytes, 28, **29**
- Lymphoma and leukemia, **129-130**
- Lymphoma, diagnosis of, 90
- M**
- Macrocytosis, caused by chemotherapy, **52**
- Macrophages, 28, **29**
- Major histocompatibility complex (MHC), 247
- Malignant mesodermal mixed tumor (MMMT), 128-**129**
- Medhosa cannula endometrial sampler, **110**
- Meigs, Joe V., 6
- Meisels and Fortin, 1976: "Condylomatous Lesions of the Cervix and Vagina, I: Cytologic Patterns," 10
- Meisels, A., 1983: "The Story of a Cell," 10, 69
- Melanoma, malignant, **130-132**
- Melting curve analysis, 331, **332, 333**
- Menopause
- appearance of cervical smears after menopause, 120-**122, 121**
- malignant mesodermal mixed tumor (MMMT), 128-**129**
- Menstrual and endocrine cycles, **21**
- Methylation, 212-214, **213, 234**
- Mi-Mark endometrial sampler, **110**
- Microarrays, genotyping, 337-341, **340**
- Microinvasive carcinoma, **86**
- Microscopy, medical and the beginnings of cytological diagnoses, 1-2
- Microspheres in HPV immunoassay, **343**
- Microtubules, 205
- Mitosis, 204, **205**
- Mole
- hydatidiform mole, 54
- invasive mole, 54
- Molecular and serologic diagnosis of HPV infections, 305-347
- Molecular assays, 307-309, **308**
- Molecular cloning, 169
- Molecular hybridization, 169
- Mucoepidermoid tumor, 101
- Müller, Johannes (1801-1858), 1
- N**
- National Cancer Institute guideline regarding ASC, 63
- Natural killer cells (NK), 247
- Nearocarcinoma (Ayre), 69
- Neoplasia
- AGC-favor neoplastic, **97-98, 97*t***, 100
- atypical endocervical cells (AGC) that favor neoplasia, **97*t***
- Neuroendocrine carcinoma, **132-133**
- Nucleic acid sequence-based amplification, **308, 310, 335-337, 340**

O

Obesity as a risk factor for endometrial cancer, 165

Omnis cellula e cellula (1855), 1

Oncogene

- and deregulated viral expression, 233-237
- biomarkers for identifying deregulated viral oncogene expression in cervical epithelium, 233-237
- viral, 208-210, **209**

Oncoproteins and immunizations, 250

Oral contraceptives

- as risk factor for cervical cancer, 159-160
- as therapy for endometrial cancer, 142
- effect on cervical smears, **120**
- pseudodecidualization of the cervix, 53

ORFs, open reading frames, of HPV, 174*t*

P

Pap smear

- conventional, 268-270
- efficacy of, 141, 142, 144-145
- exposé of 1987, 12-13, 294, 295

Pap staining technique, 269-**270**, **272**

Papanicolaou, George N. (1883-1962), 2-3

- basic studies, 3-4
- gravestone in Clinton, N.J., **15**
- New Cancer Diagnosis, 1928, **5**
- Papanicolaou and Traut, 1941, 1, **6**, **7**
- Papanicolaou, Dr. and Mrs., Cyprus postage stamp, **7**

Papanicolaou, Traut, and Marchetti, *The Epithelia of Woman's Reproductive Organs: A Correlative Study of Cyclic Changes*, 1948, 4-6

Papillary adenocarcinoma of the cervix, **101-103**

Papilloma virus *See* HPV; Virus

Parabasal cells, 26, **27**, 55, **56**, 65*t*

- and high-grade SIL, **69**
- in absence of estrogen, **123**

Parasite: *trichomonas vaginalis* (*T vaginalis*), **37-39**, **48**

Pathogen-associated molecular patterns (PAMPs), 247

Patient history, necessity for, 51, 55, 272

PCR HPV assays, 319-323, **320**

- precautions to prevent fals-positive results, 321*t*
- specific and general primer assays, 321-**322**

PCR, polymerase chain reaction, 160-161, 170, 234, **308**, 309

- commercial PCR assays, 322-326
- commercial real-time PCR for HPV, 330-334
- real-time PCR, 326-334, **327**, **329**, **332**

Pearl formations in keratinization and epidermization, **73**

Photomicrographs, first, 2

Plasma cells, **29**

Platinum loop, 12

Pouchet, F.A. (1800-1872), 2

Précis de Colpocytologie Hormonale, 1966 by J.P. Pundel, 4-6

Pregnancy

- appearance of cervical smears, 120-**122**, **121**
- Arias-Stella reaction, endocervical glands, 125, **126**, **127**
- decidualization of the cervical stroma, 52, **53**
- infections in pregnant women, 40
- pregnancy-associated lesions, 124-126, **125-127**

PreTect HPV-proofer assay, 336-**337**

Productive infection phase, HPV, **228**, 230, **231**

Progesterone

- deficiency and endometrial cancer, 165
- effect on squamous epithelium, **53**

Progestin

- for endometrial protection, 143
- for postmenopausal patients, 142

Psammomalike concretions, 28, **29**

Pseudodecidualization of the cervix, 53

Pyknosis caused by chemotherapy, 51, **52**

Pyknotic nuclei, **22**, **24-26**

Q

- Quality assurance (QA) in cervical cytology smear and tissue preparations, 265-280
- automated screening systems, 298-303
 - continuing education, 267
 - peer review, 267
 - proficiency testing, 267
 - reports and record keeping, 266, 272
 - rescreening of slides, 266
 - workload for cytotechnologists, 12-13, 266

R

- Radiation *See* Ionizing radiation
- Ramirez, E, 4
- Reagan, James W. (1918-1987), 8-9
- Replicative infection phase, HPV, **228**, **231**, 233
- Reporting cytology
- endometrial cell changes caused by IUDs, 55
 - gynecologic cytology specimens, 13-14
 - reporting endometrial cell changes, 55
 - reporting terminologies for cervical cytology and pathology, 149*t*
 - reports and record keeping, 13-14, 266, **272**
- Rhabdomyosarcoma: sarcoma botryoides (embryonal rhabdomyosarcoma), 126
- Richardson, J.G., 2
- Risk factors
- Candida infection, 39-40
 - for cervical cancer, 158-162
 - for endometrial cancer, 162-165
 - history of high-risk patients and automated screeners, 298, 298*t*
- RNA and DNA testing, 310-**312**, **311**, **334**-337
- Robotic risk management and automated systems, 302
- S**
- Safety in the cytopathology laboratory, 346
- Sarcomas, 126-128, **127**

malignant mesodermal mixed tumor (MMMT), 128-**129**

sarcoma botryoides (embryonal rhabdomyosarcoma), 126

Schleiden, M.J. (1804-1881) and Schwann, T. (1810-1882), 1

Screening

- automated screening of Pap smears, 14-15, 293-303
- automated screening systems overview, 297*t*
- biomarkers in screening of cervical cancer, 227-242
- calculating screening performance indices and relevant formulae, 138*t*
- computer devices: imagers and screeners, 289-291
- computer-assisted rescreening, 283
- effect of oral contraceptives on cervical smears, **120**
- endometrial carcinoma, 11
- endometrial carcinoma, indirect signs of, 108-109
- Federal laws governing, 294, 294*t*, 295*t*
- FocalPoint slide profiler, 289-290, 291
- for uterine cancer, 10-11, 127-132
- HPV and Pap testing compared, 147-148
- HPV as primary screening tool for cervical cancer, 147-148
- ideal tests, primary screening, **229**
- immunocytochemistry as screening tool, **237**-242
- lead-time bias: how screening can increase survival time while having no impact on mortality, 140*t*
- malignant melanoma, 130-131
- measures of improved outcome for determining screening efficacy and effectiveness, 139*t*
- novel cervical cancer screening technologies, 227-229
- programs, 11
- repair and therapy effects, squamous epithelium, 48, **49**
- reporting of gynecologic cytology specimens, 13-14
- reports and record-keeping, 13-14, 266, 272
- rescreening program, 266
- routine, need for, to diagnose SILs, 80
- routine, of asymptomatic women, 141
- specimen collection, 11-**12**

- the Bethesda System (TBS), 13-14, 294
- ThinPrep imaging system, 290-291
- to prevent uterine cancers, 137-142
- to reduce cervical cancer, 144-145
- training and regulation of practitioners, 12-13, 294
- triage, for borderline smears and HPV, 148, 149^t
- valid screening test, availability of, 137-139, 138^t, 141-142
- workload limits for cytotechnologists, 12-13, 266, 294-295, 298^t
- SEER program, population-based tumor registration, 141, 156-158, **157**
- Selective estrogen receptor modulator (SERM), 143
- Serologic and molecular diagnosis of HPV infections, 305-347
- Sexual activity
- and related risk of SILs, 79-80
 - HPV (human papilloma virus) as risk factor for cervical cancer, 160-162
- Sexually transmitted disease (STD)
- chlamydia trachomatis* (CT), 35-36
 - genital herpes, 41-42
 - HPV, 143-144, 160, 161
 - trichomoniasis, 37-38
- SILs, (squamous intraepithelial lesions) of the cervix, 63-90
- Small-cell invasive squamous carcinoma, **89-90**
- Smears
- actinomycetes, 33, **35**
 - appearance of cervical smears after menopause, 120-**122**, **121**
 - appearance of cervical smears during pregnancy, 120-**122**, **121**
 - BV (bacterial vaginosis) in conventional Pap smear, 33, **34**, **35**
 - C trachomatis* in Pap smear, **36**
 - cervical amebiasis and *Entamoeba histolytica*, **44**
 - cervical smears, general pattern of, 117-123
 - choriocarcinoma, **125**, **126**
 - cytotrophoblasts, 53-**54**
 - diagnosis and differential criteria of ASC-US and ASC-H (atypical squamous cells of undetermined significance), 64-**68**, 65^t
 - effects of estrogen, **122-123**
 - effects of estrogen and progesterone on squamous epithelium, 52, **53**
 - endometrial cytology on routine VCE smear, 104-107
 - Enterobius vermicularis*, **44**
 - fungi, *Candida* (*Torulopsis*) *glabrata* and *C albicans*, **40**, 41, 47
 - gonococcus (*N gonorrhoeae*), 33
 - inadequate smears, **273-276**
 - inflammation, **66**
 - malignant melanoma, **132**
 - malignant mesodermal mixed tumor (MMMT), 128-**129**
 - methods of detecting fungi, **40**, **41**
 - microorganisms and parasites seen on smears, 44
 - mixed or coccoid bacteria, 33, **34**, 40
 - oral contraceptives and pseudodecidualization of the cervix, 53
 - perinuclear cavity, 69, **70**
 - quality assurance (QA) in cervical cytology smear and tissue preparations, 265-280
 - syncytiotrophoblasts, **54**
 - Trichomonas vaginalis* in Pap smear, **38-39**, **47**
 - trophoblasts, 53
 - VCE smear, **269**
- Southern blot hybridization, 307, **308**, 309
- Specific and general primer assays, 321-**322**
- Spindle(s), **205**
- Squamous carcinoma
- atypical dyskeratosis (HSIL), 74-**79**
 - classification of invasive squamous carcinoma, 84-86, 85^t
 - early invasive, **87**
 - high-grade SIL, **81-84**, 85^t, **306**
 - invasive squamous carcinoma, 84-90, **85-89**
 - keratinizing, 84, **85**, 85^t, **88**
 - large-cell, 84, **85**, **89**
 - microinvasive, **86**
 - SILs, (squamous intraepithelial lesions) of the cervix, 63-90
 - SILs, (squamous intraepithelial lesions), low- and high-grade, **70**, **71**, **75-84**, **286**, **287**
 - small-cell, 84, **85**, **89**, 90

Squamous epithelium

- atrophic squamous epithelium of cervix, **55, 56**
- atrophy, **55, 56**
- atypical dyskeratosis (HSIL), **74-79**
- atypical squamous cells: ASC-US, ASC-H, **63-68, 64t, 65t**
- differential criteria between SIL and ASC-US, ASC-H, **65t**
- effects of estrogen and progesterone on squamous epithelium, **52, 53**
- histologic aspects, high-grade SILs, **83-85**
- keratinization and epidermization, **45**
- koilocytosis, koilocytes, **69-71**
- layers, **22, 23, 25**
- maternal gonadal hormones, effect on newborn girls, **117**
- repair and therapy effects, **48, 49**
- sexual activity and related risk of SILs, **79-80**
- types of cells, **25-27**

Squamous metaplasia, **44-46**

Staining

- automatic staining, **270-271**
- Pap staining technique, **269-270, 272**
- tissue sections, **280**

Standard curve, **331, 332**STI, sexually transmitted infection, HPV, **143-144**

Stromal cells

- endometrial stromal cells, **108, 109, 110**
- endometrial stromal tumor, **128**

Superficial cell, **26**SurePath and ThinPrep automated liquid-based cytology methods, **145, 277-278, 284-289, 296**Survival rates: US women with endometrial cancer, **1960-2000, 163t**Syncytiotrophoblasts, **54, 124**Syndecans, **177****T**T helper (Th) cells, **247**Tamoxifen, **143, 164-165**

- selective estrogen receptor modulator (SERM), **143**

Telomerase activity, **212**

Tests, diagnostic

- biopsy, colposcopy-directed, **142**
- colposcopy-directed biopsy, **142**
- cryotherapy, **142**
- laser fulguration or ablation, **142**

ThinPrep and SurePath automated liquid-based cytology methods, **145, 277-278, 284-289, 296**ThinPrep imaging system, **290-291, 296, 297**ThinPrep Pap test, **36**

Tissue culture

- propagation of HPV in tissue culture, **180**

Tobacco smoking as risk factor for cervical cancer, **159**Toll-like receptors (TLR), **247**Transformation zone, **22**Transvaginal ultrasound (TVUS), **141**Triage screening, for borderline smears and HPV, **148, 149t***Trichomonas vaginalis* (*T vaginalis*), **37-39, 48**

- first description, **1836, 2**
- genome, **37**
- methods of detecting *T vaginalis*, **38-39, 47**

Trophoblasts, trophoblastic tumor, **53, 54, 125**

Tumor suppressor

- genes, **211-212**
- protein and HPV, **210**

U

Uterine cancer

- annual incidence rates, **156t**
- cancer of the uterine corpus, **162-165**
- choriocarcinoma, **54, 125**
- endometrial stromal tumor, **128**
- epidemiology of uterine cancers, **155-165**
- incidence rates among racial populations, **156-158, 157t**
- leiomyosarcoma, **126-128, 127**
- lymphoma and leukemia, **129-130**
- malignant melanoma, **130-131, 130-132**

- malignant mesodermal mixed tumor (MMMT), 128-129
- neuroendocrine carcinoma, **132-133**
- prevention of, 136-150
- rare lesions of the uterus, **124-133**
- sarcomas, 126-128, **127**
- screening for, 10-11
- Uterus
- anatomy and physiology, **19-21**
 - glandular lesions of the uterus, 95-123
 - normal, 19-29
- V**
- Vaccines
- for HPV, human papilloma virus, 143-145, 218, 247-257, 346
 - prophylactic vaccines, 143, 250-252, **251**
 - second-generation vaccines, 256-257
 - therapeutic vaccines, 252-256, **253, 254**
 - vaccination, general principles of, 247
- Vacuolization, cytoplasmic, 46, **47**, 51, **52**
- Vagina, **22**
- differential diagnostic criteria of vaginal infections, 32*t*
 - endometrial cytology on routine VCE smear, 104-107
 - vaginal chloroma, **131**
 - vaginal microflora, 31-32
- VCE smear (vagina, ectocervix, and endocervix smear), 104-107
- Ventana Inform HPV Assay, 314
- Viral proteins, 334
- Virchow, Rudolph (1804-1881: *Omnis cellula e cellula* (1855), 1
- Virus *See also* HPV
- comparison of viruses, chlamydiae, and bacteria, 36*t*
 - deregulated viral gene expression, **232**
 - deregulated viral oncogene expression, 233-234
 - HSV, herpes simplex virus, 9-10
 - nonenveloped viruses, 177-178
- Virus-induced cellular changes, 9-10, 13-14, 37
- Viruslike particles (VLPs), 143, 341-342
- Vogel, Julius, 1
- W**
- Witch's milk, 117
- World Health Organization's International IARC, 161
- Y**
- Yeasts *See* Fungi

